Your session is about to expire
← Back to Search
MCLA-158 for Solid Cancers
Study Summary
This trial is testing a drug to see how safe, effective and tolerable it is for treating certain tumors.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer has spread and cannot be cured with standard treatments.I have squamous cell carcinoma of the lung.I am fully active or restricted in physically strenuous activity but can do light work.I haven't had cancer treatment in the last 4 weeks or longer.I haven't had major surgery or radiotherapy in the last 3 weeks.I have serious heart issues, but not atrial fibrillation or sudden fast heartbeats.I have no cancer history except for treated skin cancer or low-risk cancers clear for 3+ years.I am currently taking medication to suppress my immune system.I have active hepatitis B and am not on antiviral treatment.I can provide a recent tumor sample from the primary or metastatic site.I have a history of lung disease or signs of it on a chest scan.My liver disease is severe, and my cancer type is specific and aggressive.My cancer in the head, neck, stomach, or gastroesophageal junction is EGFR positive.I have had a heart attack in the last 6 months.My brain metastases are either untreated, causing symptoms, or need treatment to manage symptoms.I do not have any serious illness like uncontrolled infections or significant lung, metabolic, or mental health issues.My cancer has spread to the lining of my brain and spinal cord.I have lasting side effects from cancer treatment, but no severe nerve pain.I can undergo a biopsy.My blood pressure is high (>150/100 mmHg) despite treatment, or I have unstable chest pain.My organs are working well.I need oxygen therapy all the time due to difficulty breathing.I am not pregnant or breastfeeding and will use effective birth control during and 6 months after the study.
- Group 1: MCLA-158 + Pembrolizumab
- Group 2: MCLA-158
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the current enrollment count for this research trial?
"Affirmative. The information posted to clinicaltrials.gov verifies that this medical research is seeking participants, with 360 patients expected to be recruited from 14 locations since its initial posting in May 2018 and most recent update on February 15th 2023."
How many healthcare centers offer this clinical trial?
"This clinical trial has multiple enrolling sites, including the Hopital Saint Andre and CHU Bordeaux in Bordeaux, Centre Leon Berard in Lyon, and Hopital La Timone in Marseille. Additionally, 10 other medical centres are also offering this treatment."
Are participants being accepted for enrollment in this clinical trial at present?
"Correct. According to information available on clinicaltrials.gov, this medical research project is currently recruiting participants; it was originally posted on May 2nd 2018 and last modified on February 15th 2023. A total of 360 individuals need to be signed up from 14 diverse centres."
Share this study with friends
Copy Link
Messenger